PT3733187T - Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro - Google Patents

Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro

Info

Publication number
PT3733187T
PT3733187T PT201816162T PT20181616T PT3733187T PT 3733187 T PT3733187 T PT 3733187T PT 201816162 T PT201816162 T PT 201816162T PT 20181616 T PT20181616 T PT 20181616T PT 3733187 T PT3733187 T PT 3733187T
Authority
PT
Portugal
Prior art keywords
cancer
treatment
chiral diaryl
macrocycle
diaryl macrocycle
Prior art date
Application number
PT201816162T
Other languages
English (en)
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of PT3733187T publication Critical patent/PT3733187T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT201816162T 2015-07-21 2016-07-20 Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro PT3733187T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195081P 2015-07-21 2015-07-21
US201662302231P 2016-03-02 2016-03-02

Publications (1)

Publication Number Publication Date
PT3733187T true PT3733187T (pt) 2024-11-08

Family

ID=57834656

Family Applications (1)

Application Number Title Priority Date Filing Date
PT201816162T PT3733187T (pt) 2015-07-21 2016-07-20 Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro

Country Status (24)

Country Link
US (4) US20180325901A1 (pt)
EP (3) EP3733187B1 (pt)
JP (1) JP6817287B2 (pt)
KR (1) KR102772574B1 (pt)
CN (1) CN108026109B (pt)
AU (1) AU2016296878B2 (pt)
BR (1) BR112018001065A2 (pt)
CA (1) CA2992324A1 (pt)
DK (2) DK3325488T3 (pt)
ES (2) ES2993492T3 (pt)
FI (1) FI3733187T3 (pt)
HR (1) HRP20241615T1 (pt)
HU (1) HUE070316T2 (pt)
IL (1) IL256868B (pt)
LT (1) LT3733187T (pt)
MX (1) MX383823B (pt)
PL (1) PL3733187T3 (pt)
PT (1) PT3733187T (pt)
RS (1) RS66238B1 (pt)
RU (2) RU2020123800A (pt)
SI (1) SI3733187T1 (pt)
SM (1) SMT202400496T1 (pt)
WO (1) WO2017015367A1 (pt)
ZA (1) ZA201800416B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015209239C1 (en) 2014-01-24 2026-05-07 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
MX2017017097A (es) 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
PL3319969T3 (pl) * 2015-07-06 2024-06-24 Turning Point Therapeutics, Inc. Diarylowe polimorfy makrocykliczne
LT3733187T (lt) 2015-07-21 2024-12-10 Turning Point Therapeutics, Inc. Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN107267458B (zh) * 2017-07-06 2019-10-29 中南大学湘雅二医院 一种耐克唑替尼人的非小细胞肺癌细胞株h3122-cr23及其应用
CA3069232A1 (en) 2017-07-28 2019-01-31 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
US11098046B2 (en) 2017-11-10 2021-08-24 Angex Pharmaceutical, Inc. Macrocyclic compounds as TRK kinase inhibitors and uses thereof
HUE060711T2 (hu) 2017-12-19 2023-04-28 Turning Point Therapeutics Inc Makrociklusos vegyületek betegségek kezelésére
MX2020010116A (es) * 2018-03-28 2020-11-06 Fochon Biosciences Ltd Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
CN110386944B (zh) * 2018-04-16 2021-10-29 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
US12129258B2 (en) * 2018-04-25 2024-10-29 Primegene (Beijing) Co., Ltd Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
CN111918868B (zh) * 2018-05-04 2022-12-30 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
HRP20250048T1 (hr) 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba
CN111171049B (zh) * 2018-11-09 2021-06-04 山东轩竹医药科技有限公司 酪氨酸激酶抑制剂及其用途
US20220411439A1 (en) * 2019-06-19 2022-12-29 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
TW202133856A (zh) * 2019-11-27 2021-09-16 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111689883B (zh) * 2020-05-22 2022-02-11 上海应用技术大学 一种二芳基砜类化合物的合成方法
JP2023528907A (ja) * 2020-06-04 2023-07-06 シンノハブ ファーマシューティカル カンパニー,リミティド 大環状構造を有する化合物及びその使用
CN115813930A (zh) * 2021-08-17 2023-03-21 赛诺哈勃药业(成都)有限公司 大环化合物与mek抑制剂联用在用于治疗疾病药物中的用途
WO2025217347A2 (en) * 2024-04-11 2025-10-16 Bristol-Myers Squibb Company Process of preparing repotrectinib

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0690843T3 (da) 1993-03-25 2000-11-13 Upjohn Co Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet
PL182124B1 (pl) * 1993-12-07 2001-11-30 Lilly Co Eli Nowe zwiazki oraz srodek farmaceutyczny przeznaczony do leczenia powiklan cukrzycowych lub do leczenia nowotworów PL PL PL PL PL PL PL PL
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
DE60112611T2 (de) * 2000-12-08 2006-06-14 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
CA2735420C (en) * 2008-09-08 2016-06-28 Merck Patent Gmbh Macrocyclic pyrimidines as protein kinase inhibitors
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
HRP20140309T1 (hr) 2008-10-22 2014-05-09 Array Biopharma, Inc. SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
JP5624148B2 (ja) 2009-10-13 2014-11-12 エランコ・アニマル・ヘルス・アイルランド・リミテッド 大環状インテグラーゼ阻害剤
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
KR102015402B1 (ko) * 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003798A2 (pt) * 2011-08-19 2017-03-01 Merck Sharp & Dohme método para fabricar um composto, e, composto
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
WO2013132376A1 (en) 2012-03-06 2013-09-12 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
IN2014DN07384A (pt) 2012-03-09 2015-04-24 Lexicon Pharmaceuticals Inc
NZ630719A (en) * 2012-03-09 2017-01-27 Lexicon Pharmaceuticals Inc Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
AU2015209239C1 (en) 2014-01-24 2026-05-07 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
MX2017017097A (es) 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
PL3319969T3 (pl) * 2015-07-06 2024-06-24 Turning Point Therapeutics, Inc. Diarylowe polimorfy makrocykliczne
LT3733187T (lt) 2015-07-21 2024-12-10 Turning Point Therapeutics, Inc. Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CA3069232A1 (en) 2017-07-28 2019-01-31 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof

Also Published As

Publication number Publication date
ES2818528T3 (es) 2021-04-13
FI3733187T3 (fi) 2024-12-18
KR20180033194A (ko) 2018-04-02
US12310968B2 (en) 2025-05-27
PL3733187T3 (pl) 2025-01-07
ZA201800416B (en) 2021-07-28
KR102772574B1 (ko) 2025-02-24
SMT202400496T1 (it) 2025-01-14
MX2018000718A (es) 2020-01-20
EP4480543A2 (en) 2024-12-25
EP3733187A1 (en) 2020-11-04
CN108026109B (zh) 2021-03-02
CA2992324A1 (en) 2017-01-26
AU2016296878B2 (en) 2020-12-17
IL256868A (en) 2018-03-29
HRP20241615T1 (hr) 2025-01-31
WO2017015367A1 (en) 2017-01-26
US20230346786A1 (en) 2023-11-02
EP3325488A1 (en) 2018-05-30
IL256868B (en) 2021-03-25
EP3733187B1 (en) 2024-10-16
US11452725B2 (en) 2022-09-27
AU2016296878A1 (en) 2018-01-25
NZ738832A (en) 2024-08-30
MX383823B (es) 2025-03-14
JP6817287B2 (ja) 2021-01-20
RU2728579C2 (ru) 2020-07-30
ES2993492T3 (en) 2025-01-02
JP2018524382A (ja) 2018-08-30
LT3733187T (lt) 2024-12-10
EP4480543A3 (en) 2025-02-12
RS66238B1 (sr) 2024-12-31
CN108026109A (zh) 2018-05-11
HK1254606A1 (zh) 2019-07-26
DK3733187T3 (da) 2025-01-02
US20250375451A1 (en) 2025-12-11
RU2020123800A (ru) 2020-10-02
US20210030756A1 (en) 2021-02-04
EP3325488A4 (en) 2019-04-24
BR112018001065A2 (pt) 2018-09-11
DK3325488T3 (da) 2020-09-14
RU2018106245A3 (pt) 2019-12-26
HUE070316T2 (hu) 2025-05-28
US20180325901A1 (en) 2018-11-15
EP3325488B1 (en) 2020-06-24
RU2018106245A (ru) 2019-08-21
SI3733187T1 (sl) 2025-01-31

Similar Documents

Publication Publication Date Title
SI3733187T1 (sl) Kiralni diarilni makrocikel in njegova uporaba pri zdravljenju raka
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
SG11202104571RA (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
GB201511382D0 (en) Novel compounds and their use in therapy
AP2016009578A0 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
ZA201904966B (en) Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
GB201514021D0 (en) Novel Pyridines and their use in the treatment of cancer
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1, 3, 4-thiadiazole compounds and their use for cancer treatment
ZA201904967B (en) Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
IL258644A (en) 4,3,1-thiadiazole compounds and their use for cancer treatment
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
GB201514015D0 (en) Novel pyridazinones and their use in the treatment of cancer
PT3258931T (pt) Utilização do cabazitaxel no tratamento do cancro da próstata
IL269121A (en) Usl-311 for use in the treatment of cancer
IL259205B (en) Glycolipid compounds and their uses in the treatment of tumors
GB201514018D0 (en) Novel tricyclic compounds and their use in the treatment of cancer
HK40013929A (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
HK1259160A1 (en) Bis-pyridazine compounds and their use in treating cancer
GB201403086D0 (en) Selection of virus and agent useful in the treatment of cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201612793D0 (en) Therapeutic use of quesnoin in colorectal cancer treatment